Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units Print E-mail
By GLOBE NEWSWIRE   
Wednesday, 21 July 2021 11:30

WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE)

WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has cancelled 8,470,555 stock options of the Company (the “Cancelled Options”) of various directors, officers, employees and consultants of the Company. The Company also wishes to announce the issuance of 10,739,488 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the performance and restricted share unit plan of the Company dated April 21, 2021. Each exchanged RSU is exercisable into one common share of the Company (“Shares”) for a period of ten years from the date of grant. The expiry date of the RSUs and the vesting period of the RSUs vary depending on the participant.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (54 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information, please visit www.kanebiotech.com, or contact:

Marc EdwardsRay DupuisLorne Gorber
Chief Executive OfficerChief Financial OfficerInvestor Relations
Kane Biotech IncKane Biotech IncKane Biotech Inc.
[email protected][email protected][email protected]
+1 (514) 910-6991+1 (204) 298-2200 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 


Primary Logo




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter